Updated
The most significant concentration Tenax Therapeutics discloses is small number of product opportunities (levosimendan), classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Tenax Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
“10-K Item 1A: 'We are limited in the number of products we can simultaneously pursue and therefore our survival depends on our success with a small number of product opportunities.'”
“10-K Item 1A: 'We may be required to make milestone and royalty payments to the licensor of the levosimendan intellectual property in connection with the development and commercialization of levosimendan, which could adversely affect the profitability of levosimendan, if approved.'”
Tenax Therapeutics' concentration risk is high-share and pipeline-driven. The company states that it is limited in the number of products it can simultaneously pursue and that its survival depends on success with a small number of product opportunities, a high-share structural exposure that defines the business model itself rather than any single relationship. Layered onto that, the company may be required to make milestone and royalty payments to Orion Corporation, the licensor of the levosimendan intellectual property, a high-share dependency exposure that could affect the profitability of levosimendan if approved. These two exposures compound rather than diversify: the structural risk of betting the company's survival on a narrow set of product opportunities is made more acute by the fact that the flagship opportunity, levosimendan, carries its own dependency on licensing terms with Orion Corporation. A setback to levosimendan — whether from development, regulatory, or licensing-economics issues — would not be offset by other programs given how narrow the pipeline is by the company's own description. This is a clinical-stage-style concentration profile: idiosyncratic to the success of one or two assets, with the licensor relationship adding a further layer of dependency on top of already-concentrated pipeline risk, rather than a diversified, macro-cyclical exposure.
For the engine’s reasoning on TENX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| TENX● | Tenax Therapeutics, Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.